---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-005275"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2025-04-23T23:59:59+00:00"
generated_at: "2026-05-23T07:49:03.567144+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Protalix CFO Eyal Rubin resigns; to serve six-month transition through Oct 2025

## Summary
- Eyal Rubin, Sr. VP & CFO, provided six months' notice on April 21, 2025 to pursue other opportunities.
- He will continue in his role for the six-month period and assist with transition.
- Compensation Committee agreed to full salary, benefits, and equity incentives during the period.
- Upon termination, he will receive two months' salary severance and full accelerated vesting of unvested equity.
- No successor has been appointed; earlier termination possible with mutual agreement.

## SEC filing metadata
- accession: 0001558370-25-005275
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2025-04-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837025005275/0001558370-25-005275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837025005275/plx-20250421x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-005275
- JSON: https://secwatch.observer/filing/0001558370-25-005275.json
- Plain text: https://secwatch.observer/filing/0001558370-25-005275.txt

## Key facts
- Executive change
  Eyal Rubin resigned as Senior Vice President and Chief Financial Officer at Protalix BioTherapeutics, Inc..
  - Action: resigned
  - Role: Senior Vice President and Chief Financial Officer
  source text: On April 21, 2025, Eyal Rubin, Sr. Vice President and Chief Financial Officer of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”), provided the Company and the Company’s Board of Directors with six months’ notice of his resignation from his position with the Company and its subsidiary, in order to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837025005275/0001558370-25-005275-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.